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In vivo 3D measurement of 
moxifloxacin and gatifloxacin 
distributions in the mouse cornea 
using multiphoton microscopy
Seunghun Lee1,*, Jun Ho Lee1,*, Jin Hyoung Park2, Yeoreum Yoon1, Wan Kyun Chung1, 
Hungwon Tchah2, Myoung Joon Kim2 & Ki Hean Kim1,3
Moxifloxacin and gatifloxacin are fourth-generation fluoroquinolone antibiotics used in the clinic 
to prevent or treat ocular infections. Their pharmacokinetics in the cornea is usually measured from 
extracted ocular fluids or tissues, and in vivo direct measurement is difficult. In this study multiphoton 
microscopy (MPM), which is a 3D optical microscopic technique based on multiphoton fluorescence, 
was applied to the measurement of moxifloxacin and gatifloxacin distribution in the cornea. Intrinsic 
multiphoton fluorescence properties of moxifloxacin and gatifloxacin were characterized, and their 
distributions in mouse cornea in vivo were measured by 3D MPM imaging. Both moxifloxacin and 
gatifloxacin had similar multiphoton spectra, while moxifloxacin had stronger fluorescence than 
gatifloxacin. MPM imaging of mouse cornea in vivo showed (1) moxifloxacin had good penetration 
through the superficial corneal epithelium, while gatifloxacin had relatively poor penetration, (2) 
both ophthalmic solutions had high intracellular distribution. In vivo MPM results were consistent 
with previous studies. This study demonstrates the feasibility of MPM as a method for in vivo direct 
measurement of moxifloxacin and gatifloxacin in the cornea.
Moxifloxacin and gatifloxacin are fourth-generation fluoroquinolones, widely used to prevent or treat ocular 
infection. They have high potency against both gram-positive and gram-negative bacterial pathogens. As oph-
thalmic solutions, pharmacokinetic properties such as diffusion rate across the cornea and time duration of min-
imum inhibitory concentration are important1. Ocular pharmacokinetics of moxifloxacin and gatifloxacin have 
been analyzed by measuring their concentration in the tear film, cornea, aqueous humor, and vitreous humor of 
the eye using either high performance liquid chromatography (HPLC) with fluorescence detection1–3 or liquid 
chromatography with tandem mass spectrometry (LC/MS)4,5. HPLC with fluorescence detection utilizes intrinsic 
fluorescence property of moxifloxacin and gatifloxacin. Since these methods require sampling of ocular fluids or 
tissues, in vivo measurement in the cornea is difficult. Furthermore, spatial information in tissue is not available 
due to homogenization during sample preparation.
Optical microscopy for measuring moxifloxacin and gatifloxacin in the cornea will be useful by providing 
information of their spatial distribution via imaging. In vivo repetitive measurement will be possible, and longi-
tudinal imaging will allow to monitor temporal changes of their distribution. Therefore detail pharmacokinetic 
study and sample variation measurement would be possible. Various optical microscopic techniques such as con-
focal microscopy (CM) and multiphoton microscopy (MPM) have been used for measuring molecule distribu-
tion in the cornea6,7. CM is a 3D laser scanning microscopic technique based on fluorescence, where fluorophores 
are excited by absorption of single energetic excitation photon. Usually molecules are conjugated with fluorescent 
dyes such as fluorescein for CM imaging, unless they have intrinsic fluorescence. CM has been used to visualize 
corneal distribution of riboflavin based on its intrinsic fluorescence8. Both moxifloxacin and gatifloxacin have 
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intrinsic fluorescence, but their excitation spectra are in the range deep ultra-violet wavelength9,10. Therefore, 
CM is not appropriate for in vivo imaging of moxifloxacin and gatifloxacin due to phototoxicity. MPM is a 3D 
fluorescence microscopic technique based on multiphoton excitation (MPE) of fluorophores. MPE is a nonlin-
ear fluorescence process, in which fluorophores are excited by simultaneously absorbing two or more excitation 
photons, each having insufficient energy for excitation transition11,12. MPM uses longer excitation wavelengths 
than do typical fluorescence methods including CM. Therefore, MPM may be applicable to in vivo measurement 
of moxifloxacin and gatifloxacin by using near infrared excitation wavelengths, if they have intrinsic multipho-
ton fluorescence. MPM has 3D resolutions due to confinement of MPE at the focal volume of excitation light as 
nonlinear effect.
In this report, we verified and characterized multiphoton fluorescence of moxifloxacin and gatifloxacin in 
their ophthalmic solutions as well as aqueous solutions by using MPM. In vivo 3D distributions of moxifloxacin 
and gatifloxacin in the mouse cornea were measured by MPM imaging after topical administration. Temporal 
changes of their distribution were measured by longitudinal MPM imaging for 2 hours after administration.
Results
Multiphoton fluorescence characteristics of moxifloxacin and gatifloxacin. Multiphoton fluores-
cence properties of both moxifloxacin and gatifloxacin ophthalmic solutions were measured by MPM imaging, 
and their excitation and emission spectra are shown in Fig. 1(a,b), respectively. These spectra were normalized 
by the solution concentration because moxifloxacin and gatifloxacin ophthalmic solutions had different concen-
trations: 0.5% and 0.3% for moxifloxacin and gatifloxacin, respectively. In the measurement of emission spectra, 
790 nm excitation wavelength was used. Excitation and emission spectra of the two ophthalmic solutions showed 
that moxifloxacin has approximately 5–10 times stronger fluorescence than gatifloxacin. Other than the differ-
ence in fluorescence intensity, both excitation and emission spectra of the two ophthalmic solutions are similar 
in shape. Excitation spectra of both ophthalmic solutions have spectral ranges from 700 nm to 800 nm and have 
maximum intensities at 700 nm. Excitation spectra shorter than 700 nm could not be measured because of leakage 
of the excitation source in the current microscope setup and the limitation of laser tuning range. Emission spectra 
of both ophthalmic solutions have spectral ranges from 450 nm to 660 nm and have maximum intensities between 
500 nm and 550 nm. In order to verify that fluorescence of these ophthalmic solutions comes from their active 
pharmaceutical ingredients (APIs), aqueous solutions of moxifloxacin hydrochloride and gatifloxacin, APIs of 
the two ophthalmic solutions, were prepared and multiphoton spectra were measured. Aqueous solutions of 
the two APIs showed similar excitation and emission spectra as those of corresponding ophthalmic solutions 
(See Supplementary Fig. S1). Aqueous solutions of the two APIs showed slightly different fluorescence intensities 
compared to their corresponding ophthalmic solutions. Fluorescence intensities of moxifloxacin hydrochloride 
and gatifloxacin aqueous solutions were approximately 1.4 times and 0.93 times of those of corresponding oph-
thalmic solutions.
Fluorescence intensity as a function of excitation power was measured and results showed that fluorescence 
intensity was proportional to 1.89 power and 1.73 power of excitation power in cases of moxifloxacin and gati-
floxacin ophthalmic solutions, respectively. Since these power values were close to 2, it was concluded that their 
intrinsic fluorescence was two-photon fluorescence process. There was variation in fluorescence intensity of 
ophthalmic solution bottles, although shapes of excitation and emission spectra were consistent. Quantification 
of the fluorescence intensity for the concentration measurement may require pre-calibration of the ophthalmic 
solution bottle. The excitation and emission spectra shown in Fig. 1 were obtained by averaging results of multiple 
experiments.
Spatial distribution of moxifloxacin and gatifloxacin in the mouse cornea in vivo. 3D distri-
bution of moxifloxacin and gatifloxacin in the mouse cornea was visualized by MPM imaging in 15 min after 
topical administration, and results are shown in Fig. 2 (See Supplementary videos S1 and S2). MPM images 
and fluorescence intensity profiles of moxifloxacin and gatifloxacin administered mouse corneas are shown in 
Figure 1. Excitation and emission spectra of moxifloxacin and gatifloxacin ophthalmic solution samples 
measured by MPM. (a) excitation spectrum, (b) emission spectrum. M and G indicate moxifloxacin 
ophthalmic solution and gatifloxacin ophthalmic solution, respectively.
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Fig. 2(a–g,h–n), respectively. For each ophthalmic solution, MPM frontal images at 4 different depths of the 
superficial epithelium, basal epithelium, stroma, and endothelium, a MPM cross-sectional image, average 
Figure 2. In vivo MPM images and average fluorescence intensity depth profiles of moxifloxacin and 
gatifloxacin administered mouse corneas in 15 min after administration. (a–d) MPM frontal images of 
the moxifloxacin administered mouse cornea in four corneal layers of the superficial epithelium (a), basal 
epithelium (b), stroma (c), and endothelium (d). (e,f) an MPM cross-sectional image of the moxifloxacin 
administered mouse cornea and the average intensity profile with depth. (g) 3D reconstructed MPM image 
of the moxifloxacin administrated cornea. (h–k) MPM frontal images of the gatifloxacin administered mouse 
cornea in four corneal layers of the superficial epithelium (h), basal epithelium (i), stroma (j), and endothelium 
(k). (l,m) an MPM cross-sectional image of the gatifloxacin administered mouse cornea and the average 
intensity profile with depth. (n) 3D reconstructed MPM image of the gatifloxacin administrated cornea. A 
red arrow head marks a keratocyte, a blue arrow head marks the superficial epithelium, and blue dotted lines 
indicate the boundary between the epithelium and stroma. Scale bars are 100 μ m.
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fluorescence intensity profiles across the cornea, and a 3D rendered MPM image are shown. MPM frontal images 
of the moxifloxacin administered mouse cornea show strong fluorescence in the superficial and basal epithelia, 
and relatively weak fluorescence in the stroma and endothelium. Cells in the cornea including epithelial cells in 
the epithelium, keratocytes in the stroma (red arrowhead), and endothelial cells in the endothelium, are visible 
in MPM images with stronger intracellular fluorescence than outside. MPM cross-sectional image shows fluo-
rescence intensity distribution within the cornea clearly. There is a band of strong fluorescence in the superficial 
epithelium indicating moxifloxacin on the surface. Below the superficial epithelium, individual epithelial cells are 
visible and strong fluorescence is maintained across the epithelium. The stroma has much weaker fluorescence 
than the epithelium and shows sparsely distributed keratocytes. The endothelium appears as a thin and weak flu-
orescent band. The average intensity profiles with depth before and after moxifloxacin administration show only 
autofluorescence, and combination of autofluorescence and moxifloxacin fluorescence in the cornea, respectively. 
Autofluorescence in the cornea was measured by using the same excitation power as the one used for the imaging 
after moxifloxacin administration. Since autofluorescence is significantly smaller compared to moxifloxacin fluo-
rescence, it is concluded that fluorescence in the cornea after moxifloxacin administration is mostly moxifloxacin 
fluorescence. Depth profile of average fluorescence in the cornea after moxifloxacin administration shows maxi-
mum intensity on the corneal surface (or in the superficial epithelium) and then intensity decreases with depth, 
partly as the effect of topical administration and barrier function of the superficial epithelium. Fluorescence in 
the epithelium below the surface is still strong, approximately 57% of that on the surface, and decreases gradu-
ally with depth down to the basal epithelium. Fluorescence in the stroma drops to approximately 12% of that in 
the superficial epithelium and is relatively uniform across the stroma layer. Fluorescence in the endothelium is 
slightly stronger than that in the stroma.
Fluorescence distribution of the gatifloxacin administered mouse cornea is quite different from that of 
the moxifloxacin administered mouse cornea. MPM frontal images of 4 different corneal layers and a MPM 
cross-sectional image show strong fluorescence in the superficial epithelium only and weak fluorescence in the 
other lower corneal layers, indicating much less penetration of gatifloxacin in the cornea compared to moxifloxa-
cin. Like moxifloxacin, MPM images of the gatifloxacin treated cornea show stronger fluorescence inside the cells 
than outside. The depth profile of average fluorescence intensity in the gatifloxacin treated cornea shows maxi-
mum intensity on the corneal surface (or in the superficial epithelium) marked with a blue arrow head and low 
intensities close to the level of autofluorescence in the lower corneal layers. Autofluorescence of the cornea before 
gatifloxacin administration is stronger than that of moxifloxacin case by using higher excitation power for MPM 
imaging. Therefore, fluorescence intensity profile of the gatifloxacin administered mouse cornea shows almost no 
penetration of gatifloxacin in 15 min after topical administration.
Temporal changes of moxifloxacin and gatifloxacin in the mouse cornea in vivo. Temporal 
changes of moxifloxacin and gatifloxacin distribution in the mouse cornea after topical administration were 
measured by longitudinal MPM imaging for approximately two hours after administration, and results are shown 
in Fig. 3. MPM cross-sectional images of moxifloxacin and gatifloxacin administered mouse corneas before 
administration and several time points after administration from 10 min to 110 min with 20 min interval are 
shown in Fig. 3(a–g,j–p) respectively. Temporal profiles of average fluorescence intensities in 4 different layers 
of moxifloxacin and gatifloxacin administered corneas are shown in Fig. 3(h,i,q,r), respectively. In vivo longi-
tudinal MPM images and temporal intensity profiles of the moxifloxacin administered cornea show (1) before 
administration, the cornea has weak autofluorescence, (2) in 10 min after administration, the superficial and 
basal epitheliums have strong fluorescence, and the stroma and endothelium have weak fluorescence to the level 
of autofluorescence. Fluorescence intensities in the basal epithelium and stroma/endothelium are approximately 
30% and 4% of that in the superficial epithelium respectively, (3) in 30 min after administration, the superficial 
epithelium shows fluorescence decrease, and the other layers of basal epithelium, stroma, and endothelium show 
fluorescence increases. Fluorescence intensities in the basal epithelium and stroma/endothelium are approxi-
mately 45% and 13% of the maximum intensity in the superficial epithelium in 10 min after administration, (4) in 
50 min after and onward, all the corneal layers show gradual decreases of fluorescence, (5) in 130 min, the basal 
epithelium and stroma/endothelium have fluorescence intensities approximately 2–3 times stronger than the aut-
ofluorescence levels. Temporal intensity profiles of the four corneal layers show that (1) the superficial epithelium 
has a monotonic intensity decrease with time, (2) the basal epithelium has an intensity increase until 30 min after 
administration and a decrease later on, (3) the stroma and endothelium show intensity increases until 30 min and 
50 min after administration, and then slow decreases.
In vivo longitudinal MPM images of the gatifloxacin administered cornea show (1) before administration, 
the cornea has some autofluorescence, (2) in 10 min after administration, the superficial epithelium has strong 
fluorescence from gatifloxacin but the other layers have low fluorescence intensities similar to the levels of aut-
ofluorescence, (3) in 30–70 min after administration, the superficial epithelium has a fluorescence decrease and 
the other layers have gradual increases. The endothelium becomes brighter with time, and its maximum intensity 
is approximately 7% of the maximum intensity in the superficial epithelium in 10 min after administration and 
twice of autofluorescence, (4) in 90 min and onward, all the corneal layers have relatively constant intensities 
within approximately twice the autofluorescence levels. The temporal intensity profiles of the four corneal layers 
show (1) the superficial epithelium has the maximum fluorescence intensity in 10 min after administration, and 
a large intensity drop in 30 min, and relatively constant intensities from 50 min and later, (2) the basal epithelium 
has a low intensity, slightly stronger than that of autofluorescence, in 10 min after adminsteration. Its intensity has 
increases until 70 min, and a slow intensity decrease later on, (3) the stroma and endothelium has similar intensity 
patterns as that of basal epithelium.
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Discussion
MPM was applied to the measurement of moxifloxacin and gatifloxacin distribution in the mouse cornea in vivo 
by 3D imaging based on their intrinsic multiphoton fluorescence. Multiphoton fluorescence of moxifloxacin and 
gatifloxacin ophthalmic solutions was characterized by measuring their excitation and emission spectra. NIR 
Figure 3. Longitudinal in vivo cross-sectional MPM images of moxifloxacin and gatifloxacin administered 
mouse corneas in the x-z plane and temporal fluorescence intensity profiles in four different corneal 
layers for 2 hours after administration. (a–g) MPM images of moxifloxacin administered mouse corneas 
before administration, 10, 30, 50, 70, 90, and 110 min after administration. (h–l) temporal profiles of average 
intensities in the superficial epithelium, basal epithelium, stroma, and endothelium of the moxifloxacin 
administered cornea and magnified temporal intensity profiles in the lower three corneal layers. (j–p) MPM 
images of gatifloxacin administered mouse corneas before administration, 10, 30, 50, 70, 90, and 110 min after 
administration. (q,r) temporal profiles of average intensities in the superficial epithelium, basal epithelium, 
stroma, and endothelium of the gatifloxacin administered cornea and magnified temporal intensity profiles in 
the lower three corneal layers.
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excitation light from 700 nm to 800 nm could excite these ophthalmic solutions, and the fluorescence process 
turned out to be two-photon fluorescence by measuring a quadratic relationship between fluorescence intensity 
and excitation power. MPM was applied to in vivo measurement of moxifloxacin and gatifloxacin distribution 
in the mouse cornea after topical administration. Fluorescence of topically administered ophthalmic solutions 
was stronger than intrinsic autofluorescence of the untreated cornea, and their distributions in cornea were vis-
ualized clearly by MPM imaging. MPM imaging of the mouse cornea after topical administration showed that 
moxifloxacin penetrates the cornea better than gatifloxacin, consistent with previous pharmacokinetic studies 
with extracted ocular fluid. Higher lipophilicity and aqueous solubility of moxifloxacin allows better penetration 
across the cornea than gatifloxacin1,13. MPM imaging of both moxifloxacin and gatifloxacin administered corneas 
visualized cells in the cornea due to their high intracellular concentration. Longitudinal MPM imaging of the 
mouse cornea after topical administration showed temporal changes of moxifloxacin and gatifloxacin distribution 
in four different corneal layers.
MPM imaging of both moxifloxacin and gatifloxacin administrated corneas showed maximum fluorescence 
intensities in the superficial epithelium, lower fluorescence intensities in the stroma and endothelium, and almost 
negligible intensities in the aqueous humor. Maximum fluorescence intensities in the superficial epithelium 
confirmed the roles of the superficial epithelium layer as both barrier and reservoir for ophthalmic solutions14. 
Stroma and endothelium had stronger fluorescence compared to the aqueous humor partially due to higher con-
centration of moxifloxacin and gatifloxacin inside corneal cells than the outside. Likewise, dense cell distribution 
in the endothelium made higher fluorescence intensities than those in the stroma.
Fluorescence intensities in the aqueous humor were very low at the current imaging condition. It is important 
to measure drug penetration into the aqueous humor in case of prophylaxis of postoperative endophthalmitis. 
Although the current study focused on drug distribution in the cornea, sensitive measurement in the aqueous 
humor is possible in principle. It is because MPM is highly sensitive and there is no noise source such as auto-
fluorescence in the aqueous humor. MPM sensitivity was measured by using diluted moxifloxacin ophthalmic 
solution samples and the same excitation power used for the in vivo imaging was used in this measurement. 
Minimum detectable moxifloxacin concentration was approximately 1.93 × 10−5%, which is lower than that in 
the aqueous humor in previous studies1,5.
The excitation wavelength used for imaging the mouse cornea was 790 nm. Since the wavelength for maxi-
mum excitation was shorter than 700 nm, the current excitation wavelength was not optimal. However, excitation 
wavelength of 790 nm was chosen in order to minimize autofluorescence in the cornea. Most autofluorescence in 
the cornea comes from nicotinamide adenine dinucleotide (phosphate) (NAD(P)H), flavins, retinoids, lipofuscin, 
and elastin15 and this excitation becomes stronger with shorter excitation wavelengths16. Further investigation 
will be needed to find the optimal excitation wavelength, balancing between excitation efficiency and autofluo-
rescence background noise in corneal imaging.
MPM imaging of the mouse cornea after topical administration was performed three times for both moxi-
floxacin and gatifloxacin, and the results were consistent each other. However, there was fluorescence intensity 
variation among experiments, which might be partly due to sample variation. There was also fluorescence inten-
sity variation among ophthalmic solution bottles, and this variation might come from composition difference 
of the ophthalmic solutions and photo-bleaching effect during storage. Therefore, quantitative measurement of 
ophthalmic solution concentration in the cornea would require prior fluorescence intensity calibration of the 
ophthalmic solution.
All the in vivo studies were performed by using the mouse cornea, whose thickness is approximately 100 μ m. 
Therefore, the study results may not be directly applicable to large animal corneas whose thicknesses can be 
600–700 μ m. Therefore, the next step will be to make this technique applicable to larger animal corneas such as 
those of rabbits.
In vivo MPM images of the mouse cornea showed that both moxifloxacin and gatifloxacin were concentrated 
inside the cells (See Supplementary Fig. S2). This indicates that these ophthalmic solutions may be used as con-
trast agents for labeling cells and other microorganisms in cornea or other tissues. Since they are drugs approved 
for human use, this may open the possibility of using them in clinical applications as a contrast agent.
Although MPM imaging could measure moxifloxacin and gatifloxacin distribution in the mouse cornea in 
vivo by 3D imaging, this method has several limitations. 1) Visualization of the two fluoroquinolone ophthalmic 
solutions was based on their intrinsic multiphoton fluorescence. Therefore, this method is not applicable to other 
non-fluorescent drugs. 2) Although MPM enabled visualization of moxifloxacin and gatifloxacin distribution at 
the cellular level, the imaging field of view was limited to a few hundred micrometers in length. 3) MPM based 
method may not be able to perform quantitative measurements in the opaque cornea because the excitation laser 
will be attenuated during propagation through the cornea due to light scattering and the generated fluorescence 
will be attenuated accordingly. Therefore, MPM based method will be applicable to normal transparent cornea. 
4) Current MPM based measurement in the in vivo mouse cornea required mouse anesthesia during imaging 
due to slow imaging speed. Since anesthesia changes fluid dynamics on the ocular surface due to decreased tear 
production and the loss of blinking, corneal absorption of anesthetized mouse cornea can be different from that 
of unanesthetized mouse cornea17,18. We tried to avoid this artifact by closing the eyelid 30 seconds after admin-
istration and changing immersion media every 10 minutes to mimic blinking. High speed MPM methods will be 
needed for measurement without anesthesia19,20.
In conclusion, MPM was applied to characterize intrinsic multiphoton fluorescence of the two fluoro-
quinolone ophthalmic solutions. MPM imaging of the in vivo mouse cornea after topical administration directly 
visualized their distribution at the cellular level, and longitudinal MPM imaging of the same mouse cornea 
showed temporal changes of their distribution in the corneal layers. This study demonstrates the feasibility of 
MPM as a method for in vivo direct measurement of moxifloxacin and gatifloxacin in the cornea.
www.nature.com/scientificreports/
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Methods
Multiphoton microscopy system. A Leica SP5 multiphoton microscope system equipped with a Titanium 
Sapphire laser (Chameleon vision, Coherent) was used for MPM imaging. Excitation wavelength was tunable 
from 680 nm to 1080 nm. Emission light could be spectrally resolved up to 4 channels by using combinations 
of dichroic mirrors and emission filters. Measurement of the emission spectrum was also possible by spectrally 
dispersing emission light with a prism and collecting with a moving slit in the system. A 25× objective lens (HCX 
IRAPO L 25 × 0.95 NA water immersion, Leica) was used. Images in the x-y plane consisting of 512 × 512 pixels 
were typically acquired, and the field of view (FOV) was 310 μ m × 310 μ m. 3D imaging was performed by acquir-
ing multiple x-y plane images with stepwise translation in the z direction.
Reagents. Vigamox (Alcon Laboratories Inc., Fort worth, US) and Gatiflo (Handock Inc., Eun-Seong, Korea), 
which are moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions respectively, were used in both the char-
acterization of intrinsic multiphoton fluorescence and MPM imaging of the mouse cornea. In order to verify that 
multiphoton fluorescence properties of their ophthalmic solutions come from the active pharmaceutical ingredi-
ents (APIs), moxifloxacin hydrochloride (sc-205758, Santa Cruz Biotechnology Inc., Dallas, US) and gatifloxacin 
(sc-204762, Santa Cruz Biotechnology Inc., Dallas, US), were also used in the characterization.
Multiphoton fluorescence characterization. Stock ophthalmic solutions of moxifloxacin (0.5%) and 
gatifloxacin (0.3%) were used without dilution. Moxifloxacin hydrochloride and gatifloxacin were dissolved in 
distilled water at the same concentrations as the ophthalmic solution samples. Since the pH of moxifloxacin 
and gatilfoxacin ophthalmic solutions were 6.8 and 5.8, respectively, the pH values of their aqueous solutions 
were adjusted to 7 and 5.8 by adding hydrochloride and sodium hydroxide. 50 μ L of the solutions was placed 
in a well slide, coverslipped, and sealed with nail polish. The solution samples were imaged with the excita-
tion power of approximately 6 mW at the sample and the imaging speed of 0.4 frames/s. Average intensi-
ties were calculated from the image. Excitation spectra were measured by changing the excitation wavelength 
from 700 nm to 800 nm with a step size of 10 nm. Emission spectra were measured from 400 nm to 660 nm 
with a step size of 7 nm. Excitation wavelength in the emission spectrum measurement was set at 790 nm. 
Fluorescence intensity variation of the solution sample as a function of excitation power was measured in order 
to characterize the fluorescence process. The solution samples were prepared by diluting stock ophthalmic 
solutions to approximately 10–20% by mixing with phosphate buffered saline. Fluorescence intensities were 
measured with at least 5 different excitation power values, and the relationship between them was analyzed by 
linear curve fitting in log scale.
In vivo multiphoton microscope imaging of mouse cornea. For in vivo imaging of the mouse cornea, 
Balb/c female mice aged 5–6 weeks were used. These mice were bred at the animal facility of POSTECH Biotech 
Center under specific pathogen free conditions. The animal experiment method was approved by POSTECH’s 
Institutional Animal Care and Use Committee (IACUC, approval number POSTECH-2015-0030-C1). All exper-
iments were done in accordance with the approved guidelines. For in vivo MPM imaging of mouse corneas, 
mice were anesthetized with a mixture of isoflurane and oxygen gases during imaging. Body temperature was 
maintained at 37 °C with heating pads embedded in the eye holder. Ophthalmic solution of 10μ L was topically 
administered on the left eye, and the eyelid was closed for 30 seconds. A mouse eye holder was used to fix the 
mouse eye during MPM imaging. A detailed description of the mouse eye holder and surgical process was pub-
lished elsewhere21,22. A viscous liquid (GenTeal Gel, Novartis) was applied to the eyes as immersion media for the 
objective lens.
Spatial distributions of moxifloxacin and gatifloxacin in the mouse corneas were measured by performing 
MPM imaging in 15 min after topical administration. Excitation wavelength was set at 790 nm for both moxi-
floxacin and gatifloxacin. This excitation wavelength was chosen to minimize background noise due to autoflu-
orescence in the mouse cornea. Excitation power was approximately 10.4 mW and 30.8 mW at the samples for 
moxifloxacin and gatifloxacin, respectively. Emission light was collected in a single channel by using a long-pass 
filter and a short-pass filter (455–680 nm). Imaging speed was 0.2 frames/s, and approximately 50 frames in the 
x-y plane were acquired for 3D imaging with a step size of 2 μ m in the z direction. Prior to topical administration, 
MPM imaging was performed based on autofluorescence as a control. Then, MPM imaging was repeated on the 
same mouse cornea after topical administration. Temporal changes of moxifloxacin and gatifloxacin distributions 
in the mouse cornea were measured by performing MPM imaging periodically after topical administration. The 
imaging speed and excitation power were 0.8 frames/s, 15.2 mW, and 0.2 frames/s, 30.8 mW for moxifloxacin and 
gatifloxacin, respectively. Imaging was performed before administration as a control, and then every 20 min from 
10 min to 130 min after administration. All other conditions were the same as those for the spatial distribution 
measurements. These MPM imaging experiments of the mouse cornea was performed at least 3 times for each 
case in order to find the repeatability, and total 15 mice were used.
Analysis of in vivo multiphoton microscope images. The Amira software package was used for 3D 
reconstruction. 3D MPM images were analyzed to calculate depth profiles of the average fluorescence intensity. 
Since the mouse cornea is curved in shape, a small region of the 3D MPM image, which was relatively flat, was 
selected as the region of interest (ROI). The ROI was approximately 129 μ m × 129 μ m in the x-y plane. This ROI 
was sub-divided into 7 × 7 sub-blocks and average intensity values were calculated in the individual blocks (See 
Supplementary Fig. S3). The average intensity and standard deviation at each depth were calculated from the 
average intensity values of the sub-blocks.
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